Molecular targeted therapy and immunotherapy have gradually become the core of personalized treatment for CCA, especially in patients with specific gene mutations (such as FGFR2, IDH1, MSI-H, TMB-H) or ERBB2 gene amplification (Hwang et al., 2024). This evidence concerns the gene IDH1 and cholangiocarcinoma.